Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

UKONS 2018 | Real world assessment of lenalidomide toxicity in elderly relapsed myeloma

Faouzi Djebbari • 16 Nov 2018
UKONS 2018
Multiple Myeloma Lenalidomide

Faouzi Djebbari, MPharm (Hons), MSc, of Oxford University Hospitals NHS Trust, Oxford, UK, discusses his work investigating the risk of lenalidomide toxicity in older patients with relapsed multiple myeloma. He also highlights his plans for further study in this area. This interview was recorded at the UK Oncology Nursing Society (UKONS) 2018 Annual Conference, held in Glasgow, UK.

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals